- Home
- RDHL vs CNSP Comparison
RDHL vs CNSP Comparison
Compare RDHL & CNSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RDHL
- CNSP
- Stock Information
- Founded
- RDHL 2009
- CNSP 2017
- Country
- RDHL Israel
- CNSP United States
- Employees
- RDHL N/A
- CNSP N/A
- Industry
- RDHL Biotechnology: Pharmaceutical Preparations
- CNSP Biotechnology: Pharmaceutical Preparations
- Sector
- RDHL Health Care
- CNSP Health Care
- Exchange
- RDHL Nasdaq
- CNSP Nasdaq
- Market Cap
- RDHL 4.3M
- CNSP 5.6M
- IPO Year
- RDHL N/A
- CNSP 2019
- Fundamental
- Price
- RDHL $1.93
- CNSP $0.80
- Analyst Decision
- RDHL
- CNSP Hold
- Analyst Count
- RDHL 0
- CNSP 1
- Target Price
- RDHL N/A
- CNSP N/A
- AVG Volume (30 Days)
- RDHL 44.7K
- CNSP 161.6K
- Earning Date
- RDHL 08-28-2025
- CNSP 08-13-2025
- Dividend Yield
- RDHL N/A
- CNSP N/A
- EPS Growth
- RDHL N/A
- CNSP N/A
- EPS
- RDHL N/A
- CNSP N/A
- Revenue
- RDHL $8,042,999.00
- CNSP N/A
- Revenue This Year
- RDHL $381.91
- CNSP N/A
- Revenue Next Year
- RDHL N/A
- CNSP N/A
- P/E Ratio
- RDHL N/A
- CNSP N/A
- Revenue Growth
- RDHL 23.17
- CNSP N/A
- 52 Week Low
- RDHL $1.71
- CNSP $0.73
- 52 Week High
- RDHL $20.28
- CNSP $62.00
- Technical
- Relative Strength Index (RSI)
- RDHL 52.90
- CNSP 39.06
- Support Level
- RDHL $1.88
- CNSP $0.85
- Resistance Level
- RDHL $2.62
- CNSP $0.93
- Average True Range (ATR)
- RDHL 0.14
- CNSP 0.07
- MACD
- RDHL 0.02
- CNSP 0.01
- Stochastic Oscillator
- RDHL 32.89
- CNSP 0.00
About RDHL Redhill Biopharma Ltd.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is dedicated to advancing its development pipeline of clinical-stage therapeutic candidates. It also commercializes GI-related products in the U.S., including Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). Currently, the company's pipeline consists of five therapeutic candidates: Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, the majority of which are in clinical development.
About CNSP CNS Pharmaceuticals Inc.
CNS Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. It is involved in the development of Berubicin, which is a therapy for the treatment of glioblastoma. Glioblastomas are tumors that arise from astrocytes, which are star-shaped cells that make up the supportive tissue of the brain.